Back to top
more

Rapid Micro Biosystems (RPID)

(Delayed Data from NSDQ)

$3.42 USD

3.42
93,984

-0.07 (-2.01%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.43 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

908 Devices (MASS) delivered earnings and revenue surprises of -12.50% and +7.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Thermo Fisher Scientific (TMO) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of +2.68% and +1.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 3.70% and 9.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 17.33% and 5.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 8.33% and 0.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 0% and 20.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -3.57% and 10.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.13% and 1.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 3.12% and 11.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 8.33% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -43.33% and 6.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -1.47% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.11% and 15.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alphatec (ATEC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alphatec (ATEC) delivered earnings and revenue surprises of -25% and 0.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.63% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inari Medical, Inc. (NARI) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.70% and 20.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 12.68% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?